Updated: BioSpace’s List of October 2018 Life Sciences IPOs

글 내용 전체보기

Young Researchers Should Consider These 4 Pieces of Career Advice

글 내용 전체보기

FDA Works to Improve Plant and Animal Biotechnology Guidelines

글 내용 전체보기

Difficulties in Approving Depression Drugs Highlighted This Week

글 내용 전체보기

Difficulties in Approving Depression Drugs Highlighted This Week

글 내용 전체보기

Dupixent Boosts Sanofi’s Third Quarter, Which Also Benefits Regeneron

글 내용 전체보기

Is the Biotech Bull Market Over?

글 내용 전체보기

FDA Greenlights Another Indication for Merck’s Keytruda

글 내용 전체보기

It Takes Two: Gilead and Tango Partner on Immuno-Oncology

글 내용 전체보기

Pharma Execs Speak out Against Trump’s Drug Pricing Blueprint

글 내용 전체보기

Will GSK Move Away from Respiratory Treatments for a Focus on Oncology R&D?

글 내용 전체보기

A Look Back at October Life Sciences IPOs

글 내용 전체보기

Orchard Therapeutics Announces Pricing of Initial Public Offering

글 내용 전체보기

Selvita to Present New Data from its Oncology Programs at the Upcoming SITC 2018

글 내용 전체보기

As Shire deal inches forward, Takeda touts growth from its own new drugs

글 내용 전체보기

Astellas jumps into gene and cell therapy production with $255M investment

글 내용 전체보기

Dr. Reddy’s says FDA finds more issues at oncology drug plant

글 내용 전체보기

Merck beats out Roche with yet another Keytruda lung cancer approval

글 내용 전체보기

Sanofi returns to growth as promised, with Dupixent and vaccines leading the turnaround

글 내용 전체보기

바이넥스, 中즈언제약에 바이오시밀러 기술이전 체결

글 내용 전체보기

Orchard Therapeutics’ war chest balloons with $200M IPO

글 내용 전체보기